Vivien Nguyen1, Juliana Chen1,2,3, Reginald Lord2,4, Veronica Preda1. 1. Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia. 2. Healthy Weight Clinic, MQ Health, Sydney, New South Wales, Australia. 3. Susan Wakil School of Nursing and Midwifery, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. 4. Department of Surgery, School of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.
Abstract
INTRODUCTION: Weight gain during chemotherapy for breast cancer is a well-documented adverse effect. The purpose of this study was to investigate how multidisciplinary weight management involving endocrinology, dietitian, and exercise physiology care, in a real-life healthy weight clinic (HWC) would impact body weight and mass composition in breast cancer women post-adjuvant chemotherapy compared to a cohort of non-cancer women who have been matched by age, ethnicity, smoking, and menopausal status. METHODS: Body weight (kg), BMI (kg/m2), skeletal muscle mass (SMM %), fat mass (FM %), and waist circumference (cm) were collected at baseline of the first HWC appointment, 3 months after baseline, and 6 months after baseline. A total of 32 women were included, 11 in the breast cancer cohort and 21 in the control cohort, that matched inclusion and exclusion criteria based on a retrospective chart review from 28 July 2017 to 19 July 2021. RESULTS: By 6 months, the breast cancer women had a mean weight change of -6.99 kg (SD = 3.87, p = 0.003, n = 11) and change in BMI by -2.72 kg/m2 (SD = 1.62, p = 0.004, n = 11). There was a change in SMM of 1.21% (SD = 0.73, p = 0.005, n = 11), a change in FM of -2.76% (SD = 1.33, p = 0.002, n = 11), and a change in waist circumference of -8.13 cm (SD = 4.21, p = 0.031, n = 3). By 6 months in the breast cancer cohort, there was a larger change in body weight in women who did not have MetS (-8.72 kg, SD = 2.41, n = 6) in comparison to women with MetS (-2.65 kg, SD = 3.75 kg, n = 3) (p = 0.045). CONCLUSION: Findings indicate that multidisciplinary weight management has a positive role in early-stage breast cancer survival through improving body weight and mass composition. These results can add to the development of long-term treatment plans for survivors in order to shine a light on ways to reduce risk recurrence and chronic disease mortality.
INTRODUCTION: Weight gain during chemotherapy for breast cancer is a well-documented adverse effect. The purpose of this study was to investigate how multidisciplinary weight management involving endocrinology, dietitian, and exercise physiology care, in a real-life healthy weight clinic (HWC) would impact body weight and mass composition in breast cancer women post-adjuvant chemotherapy compared to a cohort of non-cancer women who have been matched by age, ethnicity, smoking, and menopausal status. METHODS: Body weight (kg), BMI (kg/m2), skeletal muscle mass (SMM %), fat mass (FM %), and waist circumference (cm) were collected at baseline of the first HWC appointment, 3 months after baseline, and 6 months after baseline. A total of 32 women were included, 11 in the breast cancer cohort and 21 in the control cohort, that matched inclusion and exclusion criteria based on a retrospective chart review from 28 July 2017 to 19 July 2021. RESULTS: By 6 months, the breast cancer women had a mean weight change of -6.99 kg (SD = 3.87, p = 0.003, n = 11) and change in BMI by -2.72 kg/m2 (SD = 1.62, p = 0.004, n = 11). There was a change in SMM of 1.21% (SD = 0.73, p = 0.005, n = 11), a change in FM of -2.76% (SD = 1.33, p = 0.002, n = 11), and a change in waist circumference of -8.13 cm (SD = 4.21, p = 0.031, n = 3). By 6 months in the breast cancer cohort, there was a larger change in body weight in women who did not have MetS (-8.72 kg, SD = 2.41, n = 6) in comparison to women with MetS (-2.65 kg, SD = 3.75 kg, n = 3) (p = 0.045). CONCLUSION: Findings indicate that multidisciplinary weight management has a positive role in early-stage breast cancer survival through improving body weight and mass composition. These results can add to the development of long-term treatment plans for survivors in order to shine a light on ways to reduce risk recurrence and chronic disease mortality.
Authors: A Vargas-Meza; M Chavez-Tostado; A O Cortes-Flores; D Urias-Valdez; M Delgado-Gomez; G Morgan-Villela; C Zuloaga-Fernandez Del Valle; J Jimenez-Tornero; R Zuloaga-Fernandez Del Valle; C Fuentes-Orozco; J García-Rentería; J Rendón-Félix; L Cuesta-Márquez; A Gonzalez-Ojeda Journal: Eur J Cancer Care (Engl) Date: 2016-08-01 Impact factor: 2.520
Authors: M M G A van den Berg; R M Winkels; J Th C M de Kruif; H W M van Laarhoven; M Visser; J H M de Vries; Y C de Vries; E Kampman Journal: BMC Cancer Date: 2017-04-12 Impact factor: 4.430
Authors: Nathalie LeVasseur; Wei Cheng; Sasha Mazzarello; Mark Clemons; Lisa Vandermeer; Lee Jones; Anil Abraham Joy; Pauline Barbeau; Dianna Wolfe; Nadera Ahmadzai; Mona Hersi; Carol Stober; Risa Shorr; John Hilton; Brian Hutton Journal: PLoS One Date: 2021-02-04 Impact factor: 3.240